May 8, 2008
Anacor To Present Clinical And Preclinical Data On Topical Anti-Inflammatory Candidates, AN2728 And AN2898, At The International Investigative Dermatology 2008 Conference

March 25, 2008
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients

October 8, 2007
GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry

October 1, 2007
Anacor Pharmaceuticals Appoints Paul Cleveland to its Board of Directors and Chairman of its Audit Committee

August 31, 2007
Anacor Files Registration Statement for Initial Public Offering

July 18, 2007
Anacor Names Christine Gray-Smith Chief Financial Officer

June 21, 2007
Anacor Identifies a Novel Mechanism for its Lead Anti-Fungal Drug, AN2690; Findings Published in Science

June 6, 2007
Anacor Clinical Study of AN2728, A Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis

February 5, 2007
Anacor Presents Research and Clinical Findings from Three Programs at AAD Meeting
View Posters: #1800, #1802, #1816, #1823, #421, #2703, #2712, #406, #717

February 2, 2007
Anacor Signs Worldwide Exclusive License Agreement With Schering-Plough for AN2690, a New Topical Anti-fungal Treatment

November 9, 2006
Anacor Begins Phase 2b Study of AN0128 in Children

September 26, 2006
Anacor Phase 2 Study of Novel Topical Antifungal for Onychomycosis Demonstrates Efficacy

September 18, 2006
Anacor Expands Clinical Development Team

September 12, 2006
Anacor to Detail Chemistry Behind Lead Compounds

September 7, 2006
Anacor to Present Efficacy Results on Lead Drug Candidates
View Posters: #091, #565, #566, #094, #346, #567

August 9, 2006
Anacor Releases Data Showing Clinical Safety of Topical Antifungal Treatment

June 15, 2006
Anacor Announces Positive Results from Phase 2 Trial of Novel Anti-Inflammatory Agent for the Treatment of Atopic Dermatitis

May 4, 2006
Anacor Presents Data on Novel Mechanism of Action for its Topical Antifungal Treatment, AN2690
View Posters: #769, #775, #750

April 19, 2006
Anacor Interim Phase 2 Study Results Show AN2690 Penetrates Nail Bed, Kills Fungi to Successfully Treat Nail Infections
View Poster

March 3, 2006
Anacor Announces Positive Phase 1 and Preclinical Data for Novel Topical Atopic Dermatitis Agent

March 1, 2006
Anacor Announces Nine Poster Presentations for Its Two Lead Product Candidates at the American Academy of Dermatology 64th Annual Meeting
View Posters

May 11, 2005
Anacor Pharmaceuticals Raises $25 Million in Series C Financing

May 11, 2005
Life Sciences Industry Veterans Join Anacor Pharmaceuticals Board of Directors

April 25, 2005
Dr. Karl Beutner Appointed Chief Medical Officer of Anacor Pharmaceuticals

March 1, 2004
Anacor Pharmaceuticals Names Dr. Jacob J. Plattner Head of Research

October 29, 2002
Anacor Pharmaceuticals Formed to Develop New Class of Therapeutics

October 29, 2002
Anacor Pharmaceuticals Raises $7 Million in Venture Financing

October 29, 2002
Anacor Pharmaceuticals Receives $21.6 Million Contract from Department of Defense